U.S. Medical Equipment Stock News

In May 2026, Raytheon, an RTX business, secured new U.S. government work ranging from next-generation naval radar software to advanced composable rocket motors, while also beginning deliveries of the Lightweight Command Launch Unit for the Javelin system to the U.S. Army. Together, these programs highlight RTX’s push toward modular, software-driven and adaptable weapon and sensor architectures that can be upgraded and tailored through software rather than repeated hardware redesigns. We’ll...

If you are wondering whether Marathon Petroleum at US$251.33 is still offering value or starting to look stretched, the headline numbers only tell part of the story. The stock has posted returns of 1.2% over the past 7 days, 8.1% over 30 days, 52.2% year to date and 60.2% over the last year, which naturally raises questions about how much of this is already reflected in the current price. Recent attention on large integrated refiners and fuels infrastructure companies has kept Marathon...

If you are wondering whether Cintas stock still justifies its price tag, the key question is how its current market value compares with what the underlying business might reasonably be worth. The share price recently closed at US$173.06, with returns that rose 0.4% over the last 7 days but declined 0.7% over 30 days, 6.4% year to date, and 22.3% over 1 year. The 3 year and 5 year returns sit at 49.3% and 106.7% respectively. Recent coverage has focused on Cintas as a long term compounder in...

LiveRamp Holdings (RAMP) has drawn fresh attention after a recent swing in performance, with the stock up about 26% over the past month and roughly 38% in the past 3 months. See our latest analysis for LiveRamp Holdings. That recent surge sits alongside a 37.1% year to date share price return and a 15.2% total shareholder return over 1 year. This suggests momentum has been building after a slower longer term record that includes a 23.4% total shareholder return decline over 5 years. If...

Magnachip Semiconductor recently announced that it showcased its Medium-Voltage MOSFET portfolio for AI server, data center, and industrial power systems at PCIM Europe 2026 in Nuremberg, Germany, highlighting solutions based on Shielded-Gate Trench technology across applications such as PSUs, HPC, solar inverters, and broader automotive and industrial power platforms. This focus on high-efficiency, high-density power architectures for AI infrastructure underscores how Magnachip is leaning...

Earlier this month, Xometry, Inc. announced that Lukas Biewald, co-founder and former CEO of Weights & Biases and current SVP of AI Initiatives at CoreWeave, joined its Board of Directors and was appointed to the Nominating and Corporate Governance Committee, effective May 20, 2026. By adding a board member whose career focuses on AI infrastructure and developer platforms, Xometry is signaling a deeper commitment to AI-driven product and operational innovation. We’ll now examine how bringing...

On May 28, 2026, Ambarella, Inc. reported first-quarter sales of US$100.36 million and a net loss of US$18.09 million, issued second-quarter revenue guidance of US$105.0–111.0 million, and Hanwha Group announced a long-term edge AI technology agreement with Ambarella valued at over US$800 million across more than ten years. This multi-generational partnership, spanning video security, robotics, industrial automation, and life sciences, positions Ambarella’s CVflow-based edge AI platform and...

IonQ stock performance snapshot Quantum computing company IonQ (IONQ) has drawn fresh attention after recent trading, with the stock closing at US$70.14. Its returns over the past month and past three months were far above its one-day move of 7.2%. See our latest analysis for IonQ. The recent 7.2% one day share price move builds on strong momentum, with a 30 day share price return of 62.8% and a very large 5 year total shareholder return. If IonQ’s run has you thinking about where else...

DigitalOcean Holdings (DOCN) is back in focus after Hippocratic AI reported its Polaris system reached 10 million patient calls with a 99.9% clinical safety score, all running on DigitalOcean's AI Native Cloud powered by NVIDIA GPUs. See our latest analysis for DigitalOcean Holdings. Despite a 4.1% decline in the 7 day share price return, DigitalOcean’s recent news flow and a 60.9% 30 day share price return suggest momentum has been building, with a very large 1 year total shareholder return...

Why Symbotic stock is drawing fresh attention Symbotic (SYM) is back on many watchlists after a sharp single day share price drop of about 9%, prompting investors to reassess how the warehouse automation specialist is currently being valued. See our latest analysis for Symbotic. That one day share price decline sits within a wider pullback, with Symbotic’s share price down 14.49% over 30 days and 24.76% year to date. However, the 1 year total shareholder return is 68.66%, so recent momentum...

Why Natural Resource Partners Is On Investors’ Radar Natural Resource Partners (NRP) has drawn investor attention after recent trading saw the stock close at $105.50. This has prompted a closer look at how its mineral rights and soda ash businesses support its current valuation. See our latest analysis for Natural Resource Partners. Recent trading has been mixed, with the share price return down about 10% over the past month and 13% over the past quarter. By contrast, the year-to-date share...

Monolithic Power Systems (MPWR) is back in focus after reporting strong first quarter results, with earnings and revenue beating estimates and fresh momentum tied to AI infrastructure and communications demand. See our latest analysis for Monolithic Power Systems. The recent Q1 beat comes on top of a powerful run, with the share price at US$1,633.17 and a year to date share price return of 74.43%. The 1 year total shareholder return of 141.74% and 5 year total shareholder return above 4x...

Growing physician adoption and patient referrals for Casgevy are putting CRISPR Therapeutics (CRSP) back in focus, as the company reports a narrower Q1 2026 loss and highlights multiple gene editing milestones ahead. See our latest analysis for CRISPR Therapeutics. CRISPR Therapeutics’ recent Q1 update and growing Casgevy uptake appear to be feeding into short term momentum, with a 1 day share price return of 5.32% and a 7 day share price return of 12.99%. However, the 90 day share price...

Abbott Laboratories (ABT) is back in focus after winning European clearance for its Libre Duo glucose ketone sensors and securing approval for its Ultreon 3.0 AI coronary imaging software. See our latest analysis for Abbott Laboratories. Despite the fresh regulatory wins for Libre Duo and Ultreon 3.0, Abbott Laboratories’ share price is down 30.5% year to date and the 1 year total shareholder return has declined 33.7%. This suggests recent momentum has faded even as product news keeps...

Event driven interest in Zeta Global Holdings stock Zeta Global Holdings (ZETA) is drawing fresh attention after joining Snowflake’s Open Semantic Interchange initiative and releasing a Forrester Consulting study on loyalty data, spotlighting its role in AI driven marketing and data interoperability. See our latest analysis for Zeta Global Holdings. Those AI and data interoperability announcements land alongside strong recent momentum, with the stock posting a 19.1% 90 day share price return...

Recent performance context for Stoke Therapeutics Stoke Therapeutics (STOK) has drawn fresh attention after recent trading left the stock at a last close of $31.61, with returns mixed across shorter and longer periods and a business still in the development stage. See our latest analysis for Stoke Therapeutics. Recent trading has been choppy, with a 7 day share price return of 6.54% but a 90 day share price return that is down 13.18%, set against a very large 1 year total shareholder return...

Q1 2027 earnings snapshot Dycom Industries (DY) opened its Q1 2027 scorecard with revenue of about US$2.0b and basic EPS of US$3.05, setting a clear marker for how the current trading price of US$535.20 lines up with the underlying business. Over the past year, revenue has moved from US$1.26b in Q1 2026 to US$2.0b in Q1 2027, while quarterly basic EPS shifted from US$2.11 to US$3.05. This sits against a backdrop of trailing twelve month basic EPS of US$10.62 on revenue of roughly US$6.3b,...

Arbor Realty Trust (ABR) recently redeemed $787.0 million of legacy CLO 17 notes and moved about $1.21 billion of assets into repurchase facilities with JPMorgan, securing better terms and creating roughly $132.3 million of liquidity. See our latest analysis for Arbor Realty Trust. Despite the refinancing progress, the stock has had a weak run, with a 30-day share price return down 29.9% and a 1-year total shareholder return down 35.1%. This indicates that momentum has been soft even as...

At its 2026 Annual Meeting of Shareholders held on May 20, Seacoast Banking Corporation of Florida approved an amendment to its Amended and Restated Articles of Incorporation to declassify its Board of Directors. This shift away from a staggered board structure meaningfully alters the company’s governance framework, potentially increasing director accountability and influencing longer-term decision-making. Next, we’ll examine how declassifying the Board of Directors could influence...

Las Vegas Sands stock at a glance Las Vegas Sands (LVS) is back in focus for investors, with the stock recently closing at US$51.11 and posting mixed returns over the past month and past 3 months. See our latest analysis for Las Vegas Sands. Recent trading shows a short-term rebound, with a 7 day share price return of 3.36%, but the stock is still down 21.62% year to date while the 1 year total shareholder return is 26.48%. This combination suggests shifting views on both risk and income. If...

REalloys stock performance snapshot after recent moves REalloys (ALOY) has drawn fresh attention after recent trading moves, with the stock last closing at $9.73 and showing mixed performance across different periods, including gains over the past month and a decline over the past 3 months. See our latest analysis for REalloys. Recent trading has been choppy, with a 30 day share price return of 8.35% contrasting with a 90 day share price decline of 47.29%. The 1 year total shareholder return...

Elanco Animal Health (ELAN) has kicked off a phased launch of Befrena, an anti IL 31 monoclonal antibody injection for canine allergic and atopic dermatitis, giving investors fresh information on its pet dermatology portfolio. See our latest analysis for Elanco Animal Health. Elanco's recent Befrena launch comes as momentum in the stock has picked up in the short term, with a 7 day share price return of 12.48% and a 1 month share price return of 8.26%, even though the 3 month share price...

Sysco (SYY) recently attracted fresh attention after receiving a 2026 Newsweek AI Impact Award for its company-wide artificial intelligence program, raising questions about how this digital shift might factor into the stock’s long term story. See our latest analysis for Sysco. At a share price of $75.92, Sysco has seen its 30 day share price return rise 3.48%, even though the 90 day share price return has fallen 16.72%. The 1 year total shareholder return of 8.37% points to steadier long term...

Wondering if Prosperity Bancshares at around US$69.31 a share reflects good value? This article walks through what the current price might be implying about the stock. The stock has been fairly steady lately, with a 0.3% return over the last 7 days, a slight 0.2% decline over 30 days, a 0.5% decline year to date, and a 2.3% return over the last year, alongside longer term returns of 31.9% over 3 years and 5.9% over 5 years. Recent coverage has focused on how regional banks are balancing...